Savara’s (SVRA) Market Outperform Rating Reiterated at JMP Securities

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $8.00 price objective on the stock. JMP Securities’ target price suggests a potential upside of 62.93% from the stock’s previous close.

Separately, Piper Sandler upped their target price on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $8.20.

Savara Price Performance

Shares of NASDAQ SVRA traded down $0.05 during midday trading on Thursday, hitting $4.91. 514,334 shares of the company’s stock were exchanged, compared to its average volume of 841,814. Savara has a 12-month low of $1.76 and a 12-month high of $5.70. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. The company has a market cap of $678.32 million, a price-to-earnings ratio of -14.91 and a beta of 0.77. The business’s fifty day moving average price is $4.97 and its two-hundred day moving average price is $4.39.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, research analysts forecast that Savara will post -0.38 EPS for the current fiscal year.

Institutional Trading of Savara

Several hedge funds and other institutional investors have recently bought and sold shares of SVRA. State Street Corp boosted its stake in Savara by 12.4% in the first quarter. State Street Corp now owns 271,611 shares of the company’s stock worth $356,000 after buying an additional 30,062 shares in the last quarter. Renaissance Technologies LLC lifted its position in Savara by 235.3% in the second quarter. Renaissance Technologies LLC now owns 56,000 shares of the company’s stock valued at $85,000 after purchasing an additional 39,300 shares during the last quarter. Millennium Management LLC lifted its position in Savara by 12.3% in the second quarter. Millennium Management LLC now owns 156,314 shares of the company’s stock valued at $238,000 after purchasing an additional 17,093 shares during the last quarter. Jane Street Group LLC bought a new stake in Savara in the third quarter valued at approximately $26,000. Finally, Kayne Anderson Rudnick Investment Management LLC bought a new stake in Savara in the third quarter valued at approximately $1,887,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.